In the 52‐week studies, maximum reductions in median percentage change in serum total IgE from −70.0% to −76.7% were observed in AD (CHRONOS), asthma and CRSwNP patients in the dupilumab‐treated groups by the end of treatment (all p < .0001 versus placebo). This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.